This study is looking at whether adding Mindfulness-Oriented Recovery Enhancement (MORE) to ketamine-assisted psychotherapy can help people with opioid use disorder (OUD) reduce their opioid use and cravings more effectively. You could be eligible if you are 18 or older, speak English, have OUD, are currently using illicit drugs or report it, and are taking buprenorphine (a medication for OUD). The study will compare two groups: one receiving ketamine with MORE, and another receiving ketamine with a general support group. The main goal is to see if the group receiving MORE has greater reductions in opioid use between day 15 and day 84 of the study. The study aims to enroll 88 participants.

Study design

This is a randomized controlled trial where 88 participants will be randomly assigned to one of two groups. Both groups will receive ketamine-assisted psychotherapy, but one group will also receive Mindfulness-Oriented Recovery Enhancement, and the other will receive a support group.

What's involved

Participants will complete assessments at the beginning, during, after treatment, and at follow-up. The specific number of visits or procedures is not detailed.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed after treatment, with the primary outcome measured from day 15 through day 84.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.